

RESEARCH

Open Access



# Plasmid mediated colistin resistant *mcr-1* and co-existence of *OXA-48* among *Escherichia coli* from clinical and poultry isolates: first report from Nepal

Bijaya Muktan<sup>1†</sup>, Upendra Thapa Shrestha<sup>1†</sup>, Binod Dhungel<sup>1</sup>, Bagish Chandra Mishra<sup>2</sup>, Nabaraj Shrestha<sup>3</sup>, Nabaraj Adhikari<sup>1</sup>, Megha Raj Banjara<sup>1</sup>, Bipin Adhikari<sup>4</sup>, Komal Raj Rijal<sup>1\*</sup> and Prakash Ghimire<sup>1</sup>

## Abstract

**Background:** Plasmid-mediated resistance to the last-resort drugs: carbapenems and colistin is an emerging public health threat. The studies on the prevalence and co-expression of resistant genes among livestock and human pathogens are rare in Nepal. This is the first study in Nepal exploring the prevalence and co-existence of colistin resistance gene, *mcr-1* along with carbapenemase resistance gene, *OXA-48* in *Escherichia coli* isolated from poultry and clinical specimens.

**Methods:** A total of 240 rectal swabs from chickens of five different poultry farms of Kathmandu valley and 705 mid-stream urine samples from human subjects attending Kantipur Hospital, Kathmandu were collected between August, 2018 and March, 2019. Rectal swabs and urine specimens were cultured. *E. coli* isolated from the specimens were screened for antimicrobial susceptibility testing (AST) using disk diffusion method. Minimum inhibitory concentration (MIC) of colistin was determined by agar dilution method using 0.5 µg/ml to 32 µg/ml. The *E. coli* isolates were first screened for *mcr-1* followed by screening for *OXA-48* genes using conventional Polymerase chain reaction (PCR).

**Results:** Of the total samples analyzed, *E. coli* was isolated from 31.7% (76/240) of poultry and 7.9% (56/705) of clinical specimens. In AST, 80% (61/76) of *E. coli* from poultry and 79% (44/56) from clinical specimens were MDR. The phenotypic prevalence of colistin resistance in poultry specimens were 31.6% (24/76) and clinical specimens were 21.4% (12/56). In PCR assay, 27.6% (21/76) of poultry and 19.6% (11/56) of clinical isolates had colistin resistant *mcr-1* gene. MICs value of *E. coli* isolates ranged from 4 to 32 (µg/ml) in both clinical and poultry isolates. Prevalence of co-existing carbapenem resistance gene, *OXA-48*, among colistin resistant *mcr-1* positive isolates was 38% (8/21) in poultry specimens and 18.2% (2/11) in clinical specimens.

**Conclusions:** The high prevalence of colistin and carbapenem resistant genes, and their co-existence in plasmid DNA of *E. coli* isolates in this study suggests the possible spread to other animal, human and environmental pathogens. Molecular methods in addition to the conventional diagnostics in laboratories can help in early diagnosis, effective management and control of their potential transmission.

\*Correspondence: komal.rijal@cdmi.tu.edu.np

<sup>†</sup>Bijaya Muktan and Upendra Thapa Shrestha contributed equally to this work

<sup>1</sup> Central Department of Microbiology, Tribhuvan University, Kirtipur, Kathmandu, Nepal

Full list of author information is available at the end of the article



**Keywords:** *mcr-1*, OXA-48, Colistin resistant *E. coli*, MDR, Polymerase chain reaction

## Background

The plasmid-encoded colistin resistant gene, *mcr-1* was first reported in *E. coli* isolates from livestock and human specimens in China [1]. Until the discovery of *mcr-1*, all reported polymyxin resistance mechanisms were chromosomally mediated, due to mutation and regulatory changes [2], and had never been reported to occur via horizontal gene transfer [3]. Two earlier mechanisms: natural and phenotypic mechanisms were suggested among colistin resistant strains, the former occurring via mutations of bacterial genomes while the latter was the result of adaptive mechanism [3]. A number of *mcr-1* strains have been reported worldwide among several species of *Enterobacteriaceae* in a short span of time since its first report in 2016 [4].

*mcr-1* gene is not only limited to *E. coli* but also has been spreading among other members of *Enterobacteriaceae* co-existing with other resistance genes [5]. Several retrospective studies performed worldwide showed that *mcr-1* had been circulating undetected for at least 20 years [6]. Subsequent findings of 11 new genetic variant of *mcr-1* across different countries show increasing divergence of colistin resistance mechanism [7]. There is a strong association of ISApI1 genomic insertion site and *mcr-1*, which causes demographic expansion and global distribution [2]. Furthermore, insertion of *mcr-1* into *E. coli* chromosomes may enable it to become intrinsically resistant, which is expected to become more prevalent in future [8].

*mcr-1* genes carrying colistin resistant *E. coli* isolates are challenging 'one health' concept as these strains have been isolated from humans, animals, and environments from all continents [9]. Finding of *mcr-1* gene carrying bacteria in natural environments shows possibility of transference of *mcr-1* carrying *Enterobacteriaceae* to humans via food chain [10].

There is a growing number of findings reporting the rapid surge of carbapenemase including *blaVIM-1*, *blaNDM-1* and OXA-48 among carbapenem resistance *Enterobacteriaceae* (CRE) in human beings [1, 11, 12], though the CRE is still rare in animals [13]. The emergence and global spread of co-existing carbapenem resistance with plasmid-mediated colistin resistance (*mcr-1*) in gram-negative bacterial pathogens, particularly among the members of *Enterobacteriaceae* can be catastrophic [13, 14]. There is an increasing concern on the co-existence of colistin and carbapenem resistances in *Enterobacteriaceae* from human and animal samples, because

this combination can limit the therapeutic options in the treatment of MDR bacteria [4, 15].

In Nepal, there is a pervasive use of antibiotics in food animals farming as growth promoters in addition to indiscriminate over the counter use among humans [16, 17]. The colistin resistance can increase in exponential proportion because of its widespread use in food animals and human beings and has been supported by the detection of *mcr-1* gene from environment, food, animals and human beings [18]. Although global reports on colistin resistance in human and environment are increasing [19], there is only one previous report till date from Nepal. Recent studies reported from Nepal showed 26.66% of colistin-resistant *E. coli* harbored *mcr-1* gene isolated from the chicken meats [20] and 33.3% of carbapenem resistant *E. coli* harbored OXA-48 isolated from urine samples [21]. The main objective of this study was to explore the prevalence and co-existence of colistin resistance gene, *mcr-1* along with carbapenemase resistance gene, OXA-48 in *Escherichia coli* isolated from poultry farms located in Kathmandu, Kavrepalanchok and Bhaktapur and human specimens (urine) from patients attending Kantipur Hospital, Tinkune, Kathmandu between August, 2018 and March, 2019.

## Methods

### Study design and study sample

This cross-sectional study was carried out between August 2018 and March 2019 in Bhaktapur Kavrepalanchok, and Kathmandu districts. The clinical specimens were collected from Kantipur Hospital, Tinkune Kathmandu. The study subjects included patients of all ages and both gender (male and female) attending the hospital with suspicion of UTI and all of the participants provided written informed consent to participate in the study. A total of 705 mid-stream urine samples from patients (male, N = 315 and female, N = 390) suspected of urinary tract infection (UTI) were collected in a sterile, clean, well-labeled, and leak proof container with no visible signs of contamination and were transported to laboratory [22].

The poultry specimens were collected from selected poultry farms in Kavrepalanchok (Panauti), Bhaktapur (Darjeeling Height, Duwakot), Kathmandu (Sundarijal and Dhakal Gau). A total of 240 rectal swabs of chicken were collected and inoculated into buffered peptone water, kept in insulated ice-cold box and were transported to laboratory within 1 hour.

### Culture of specimens and identification of the isolates

The samples were observed for macroscopic, microscopic and culture characteristics. Urine samples were inoculated on Cysteine Lactose Electrolyte Deficient (CLED) (Hi Media, India) agar using a standard calibrated loop (4 mm). The collected rectal swabs with inoculated tubes were incubated for 18–24 h at 37 °C, and were sub-cultured on MacConkey agar (MA) (Hi Media, India). Inoculated CLED media plates were incubated aerobically at 37 °C for 18–24 h. Thus, obtained colony growth of gram-negative rods suspected of *E. coli* were further sub-cultured aerobically on Nutrient Agar (NA) from both MA and CLED media plates. *E. coli* from both specimens was identified on the basis of colony morphology, staining, biochemical tests and a greenish-metallic sheen of colonies formed on Eosin Methylene Blue (EMB) agar [23, 24].

### Antibiotic susceptibility test (AST)

All isolates of *E. coli* were tested for antibiotic susceptibility using modified Kirby Bauer disc diffusion method based on the Clinical and Laboratory Standard Institute guidelines [25]. Isolates were tested for resistance against amoxiclavate (30 µg), ceftazidime (30 µg), cefixime (5 µg), ciprofloxacin (5 µg), gentamicin (10 µg), imipenem (10 µg), meropenem (10 µg), piperacillin/tazobactam (100/10 µg) and tetracycline (30 µg) (HiMedia, India). Results were interpreted as sensitive, intermediate and resistant [25]. Isolates showing non-susceptibility (either resistance or intermediate) to at least one antimicrobial agent in three or more of the categories were considered as multi-drug resistant (MDR) [26].

### Screening of colistin resistant *E. coli*

In AST, minimum inhibitory concentration (MIC) for colistin was determined by agar and broth micro-dilution methods using 0.5 µg/ml to 32 µg/ml. *E. coli* isolates showing visible growth on colistin concentration of 2 µg/ml or more than 2 µg/ml were detected as colistin resistant isolates [25].

### Extraction of plasmid DNA and PCR amplification of colistin resistance gene (*mcr-1*)

The plasmid DNA was extracted using alkaline lysis method. The extracted plasmids were then suspended in TE buffer, labeled well and stored at – 20 °C [27]. *mcr-1* gene of plasmid carried by *E. coli* isolates was amplified using primer pairs CLR5-F (5'CGGTCAGTCCGT TTGTTTC-3') and CLR5-R (5'-CTTGGTCGGTCTGTA GGG-3') as forward and reverse primers [1]. Reaction volume was set as 25 µl by adding 21 µl of 1X master mix, 0.5 µl each of forward and reverse primer and 3 µl

of DNA template. The optimized PCR amplification of *mcr-1* gene is 95 °C for 15 min to activate hot-star; 30 cycle of denaturation at 94 °C for 30 s; annealing at 57 °C for 1:30 min; extension at 72° for 1:30 min, and final extension at 72 °C for 10 min and holding at 4 °C for 10 min.

### PCR amplification of carbapenem resistance gene (OXA-48)

OXA-48 gene responsible for the resistance of carbapenem drug was amplified using primer pairs as forward sequence OXA-48\_forward primers (FP) (5'GCTTGA TCGCCCTCGATT-3') and reverse sequence OXA-48\_reverse primers (RP) (3'GATTTGCTCCGTGGC CGAAA-5'). Reaction volume was set as 25 µl by adding 21 µl of 1× master mix, 0.5 µl each of forward and reverse primer and 3 µl of DNA template. The optimized PCR amplification of OXA-48 gene is 95 °C for 15 min to activate the hotstar, 30 cycle of denaturation at 94 °C for 30 s, annealing at 57 °C for 1:30 min and extension at 72° for 1:30 min and final extension at 72 °C for 10 min and holding at 4 °C for 10 min [28].

### Agarose gel electrophoresis

The agarose gel electrophoresis of extracted plasmid DNA and amplified PCR product was performed, followed by confirmation of *mcr-1* and OXA-48 gene by visualizing in UV transillumination [28].

## Results

### Distribution of samples and prevalence of *E. coli* in poultry and clinical specimens

The distribution of poultry samples according to farms with previous history of vaccination, colistin antibiotic use, number of samples collected, number of *E. coli* isolates and the presence of colistin resistant isolates are illustrated in Table 1. The growth pattern observed in samples from each farm is presented in Fig. 1. Overall, the prevalence of *E. coli* in poultry specimens was (31.7%;76/240) whereas it was (7.9%; 56/705) in clinical specimens.


Among 705 urine specimens, (18.4%; 130/705) showed bacterial growth. Of 130 bacterial growth, (43%;56/130) were *E. coli*. On age wise distribution of UTI patients, 44.6% (58/130) were from age group (16–45) years, (32.3%;42/130) were from age group > 45 years and (23.1%; 30/130) were from age group (0–15) years respectively.

### Antibiotic susceptibility test (AST) of *E. coli* isolates

Among the total of 76 *E. coli* isolates from poultry, highest resistance was found in tetracycline (67.1%; 51/76) followed by amoxiclavate (55.3%; 42/76), ciprofloxacin (50%;38/76), nalidixic acid (50%;38/76) and imipenem

**Table 1 Farm wise epidemiological data of colistin resistant *E. coli***

District	Poultry sites	Number of samples taken	Vaccination	Use of colistin	<i>E. coli</i> isolated	Colistin resistant <i>E. coli</i> isolated
Kavrepalanchok	Panauti	40	+	-	5	2
Bhaktapur	Duwakot	50	+	-	16	9
	Darjeling Height	50	+	+	26	6
Kathmandu	Sundarijal	50	+	+	15	2
	Dhakal Gau	50	+	+	14	2
Total		240			76	21



**Fig. 1** Farm wise growth distribution of *E. coli* isolates

(32.9%;25/76). Similarly, among the total of 56 *E. coli* isolates from clinical specimen, highest number of isolates were resistant to cefixime (71.6%;40/56) followed by ceftazidime (66.1%;37/56), ciprofloxacin (53.6%;30/56) and piperacillin/ tazobactam (39.3%;22/56) (Table 2).


In AST, (80%; 61/76) of poultry specimens and (79%; 44/56) of clinical specimens were MDR (Fig. 2).

**Antimicrobial resistance phenotypes of clinical and poultry *E. coli* isolates**

Antibiotic resistance pattern of MDR *E. coli* isolates were determined by 12 different antibiotic resistance phenotypes (R- phenotypes). Among them the most resistant pattern in poultry *E. coli* isolates were imipenem-tetracycline-amoxiclav (21%; 16/76) followed by imipenem-ciprofloxacin-amoxiclav (19.7%; 15/76) and

**Table 2 Antibiotic resistance profile of *E. coli* isolated from poultry and clinical specimens**

Antibiotics	Resistance (%)	
	Poultry (n = 76)	Clinical (n = 56)
Amoxiclav (30 µg)	42 (55.3)	3 (5.4)
Ceftazidime (30µ g)	4 (5.3)	37 (66.1)
Cefixime (5 µg)	10 (13.2)	40 (71.4)
Ciprofloxacin (5 µg)	38 (50)	30 (53.6)
Gentamicin (10 µg)	21 (27.6)	12 (21.4)
Imipenem (10 µg)	25 (32.9)	2 (3.6)
Meropenem (10 µg)	2 (2.6)	0
Nalidixic acid (30 µg)	38 (50)	11 (19.6)
Piperacillin/Tazobactam (100/10 µg)	0	22 (39.3)
Tetracycline (30 µg)	51 (67.1)	21 (37.5)



**Table 3** Antibiotic resistance phenotypes of *E. coli* isolated from poultry and clinical specimens

S.N	Antimicrobial resistance pattern	Poultry <i>E. coli</i> Resistant isolates N (%)	Clinical <i>E. coli</i> Resistant isolates N (%)
1	CIP/TE/NA	14 (18.4)	2 (3.6%)
2	CIP/GEN/AMC	9 (11.8)	
3	IMP/TE/AMC	16 (21)	
4	IMP/CIP/AMC	15 (19.7)	
5	CFM/NA/TE	3 (4)	5 (8.9%)
6	GEN/NA/AMC	10 (13.2)	
7	IMP/CAZ/CIP	1 (1.3)	1 (1.8%)
8	CAZ/CFM/TE	2 (2.6)	12 (21.4%)
9	GEN/IMP/CIP	3 (4)	1 (1.8%)
10	CIP/TE/GEN/AMC	4 (5.2)	
11	TE/AMC/GEN/NA	6 (8)	
12	CIP/TE/AMC/NA	8 (10.5)	

AMC Amoxiclave, CAZ Ceftazidime, CFM Cefixime, CIP Ciprofloxacin, GEN Gentamicin, IMP Imipenem, NA Nalidixic acid, TE Tetracycline

ciprofloxacin- tetracycline-nalidixic (18.4%; 14/76). Among clinical *E. coli* isolates, the most resistant pattern was ceftazidime-cefixime-tetracycline (21.4%; 12/56) followed by cefixime-nalidixic acid-tetracycline (8.9%; 5/56) (Table 3).

**Determination of MIC and colistin resistant *E. coli* isolates**  
MICs value of *E. coli* isolates ranged from 4 to 32 (µg/ml) in both clinical and poultry *E. coli* isolates (Table 4). In this assay, 31.6% (24/76) of poultry isolates and 21.43%

**Table 4** MIC colistin resistant *E. coli* isolates of poultry and clinical specimens

S. No	Colistin concentration (MIC)	Resistant isolates		P-value
		Poultry (n = 24)	Clinical (n = 12)	
1	4 (µg/ml)	4 (16.7)	3 (25)	0.8
2	8 (µg/ml)	5 (20.8)	2 (16.7)	
3	16 (µg/ml)	7 (29.2)	4 (33.3)	
4	32 (µg/ml)	8 (33.3)	3 (25)	


**Table 5** Distribution of colistin resistance, mcr-1 gene and OXA-48 gene among *E. coli* isolates of poultry and clinical specimens

Colistin resistant <i>E. coli</i> isolates		mcr-1 gene among colistin resistant <i>E. coli</i> isolates		OXA-48 gene positive isolates in mcr-1 gene positive <i>E. coli</i>	
Poultry (n = 76)	Clinical (n = 56)	Poultry (n = 24)	Clinical (n = 12)	Poultry (n = 21)	Clinical (n = 11)
24 (31.6%)	12 (21.4%)	21 (87.5%)	11 (91.6%)	8 (38%)	2 (18.2%)

(12/76) of clinical isolates were confirmed as colistin resistant (Fig. 2) (Table 5).

**Prevalence of mcr-1 gene among colistin resistant clinical and poultry *E. coli* isolates**  
All *E. coli* isolates were screened for plasmid mediated mcr-1 gene using conventional PCR. In PCR assay,

colistin resistance was found to be 27.6% in poultry isolates and 19.6% in clinical isolates. Among phenotypic colistin resistance, 87.5% (21/24) *E. coli* isolates from poultry specimens were tested positive for *mcr-1* gene and 91.6% (11/12) of the clinical isolates (*E. coli*) were tested positive for *mcr-1* gene (Table 5). The *mcr-1* with 309 bp size is presented in Fig. 3.




**Fig. 3** *mcr-1* gene in colistin resistant *E. coli* (Lane1, marker DNA (100–1000 bp), Lane L2 (positive control), L3, L6, L7 and L8 *mcr-1* positive (309 bp)

**OXA-48 gene among *mcr-1* positive colistin resistant *E. coli* isolates**

In this assay, 38% (8/21) of poultry isolates and 18.2% (2/11) of clinical isolates had carbapenem resistant OXA-48 gene (Table 5). The amplified OXA-48 gene with 290 bp is illustrated in Fig. 4.

**Discussion**

This is the first report of plasmid mediated colistin resistance *mcr-1* gene and OXA-48 gene among *mcr-1* positive colistin resistant *E. coli* isolates from clinical and poultry specimens of Nepal. In this study, using PCR assay, colistin resistance was found to be 27.6% in poultry isolates and 19.6% in clinical isolates. The emergence and spread of CRE has obliged clinicians to use colistin—a drug notorious for its toxicity [29]. Colistin is the last resort drugs for these resistant isolates [30]. Increasingly over the recent years, morbidity, mortality and the economic consequences associated with colistin resistance are reported [31]. *mcr-1* recently identified as resistance and transferable gene has been recovered from healthy carriers, food, environmental sources and clinical isolates [14]. Most of the *mcr-1* positive strains have been proven to be carrying different carbapenemase genes such as *bla*NDM-9, *bla*NDM-5, *bla*VIM-1, *bla*OXA-48-type, and *bla*KPC- 2 [32]. This combination further limits the



**Fig. 4** OXA-48 gene among *mcr-1* positive *E. coli* isolates (Lane M, marker DNA (100–1000 bp), lane 5, 6 and 3, OXA-48 gene (290 bp)

therapeutic options because both last resort drugs: colistin and carbapenems are challenged by this phenomenon [4]. Our study also confirmed the substantial presence of *mcr-1* and *blaOXA-48* among isolates of human and animal (poultry) origin.

In our study, 32% *E. coli* were isolated from poultry specimens consistent with a previous study that reported 36.4% growth of *E. coli* from poultry fed with colistin in Central Nepal [20]. Research conducted in China showed higher (80%) growth of *E. coli* from rectal swab of food animals [33]. The increased and variable rate of colistin resistance may be due to quality, concentration and extensive use of colistin in the livestock farming [34]. In clinical samples, *E. coli* remains as the most frequently isolated organisms which is consistent with several previous studies from Nepal [35–38]. The higher load of *E. coli* in urine samples may be due to their main role in urinary tract infections [35].

AST of poultry isolates showed more than 50% of resistance to most of the antibiotics used in this study. Similar resistance pattern was screened in China [2]. Another study reported from Iran had showed 77.7% resistance to ciprofloxacin, 33.3% resistance to gentamicin but no resistance to Imipenem [39]. A study from China reported higher rate of resistance to tetracycline (90%), cefixime (71.4%), and ceftazidime (66.1%) in *E. coli* isolates [33]. Another study from Pakistan reported higher resistance to gentamicin (77%) and ciprofloxacin (65%) in clinical isolates of *Enterobacteriaceae* [40]. Higher (79%) prevalence of multi-drug resistant isolates in our study is consistent with previous studies from Nepal [21, 41] and Pakistan [40]. The higher load of MDR isolates may be due to significant antibiotic pressure in the environment, irrational dose regimens, use in food animals and transmission of resistant isolates between people, animal and the environment [40]. In our study, 80% (61 out of 76) of *E. coli* from poultry were found to be MDR. Our finding was consistent with a study from Bharatpur, Nepal that showed MDR rate as 79.6% in poultry meat [42]. However, similar study from Bangladesh reported 100% MDR in *E. coli* isolates [43]. Open access between poultry farms and communities, unhygienic practice, inappropriate use of antibiotics, are some of the reasons attributed for emerging resistance patterns including MDRs in Nepal [33, 43, 44].

In this study, MIC value of colistin was observed up to 32 mg/L and found similar (4–32 µg/ml) dose in both poultry and clinical specimen. Most of the isolates of clinical specimen showed MIC value of 16 µg/ml while those *E. coli* isolates from poultry showed 32 µg/ml. Studies from Vietnam have reported lower MIC value of clinical isolates as 4 (µg/ml) [45] and MICs range of 4 to 16 µg/ml in *E. coli* isolates were reported from Chinese

University Hospital [46]. The greater MIC value revealed these *E. coli* isolates as non-wild type [47]. The presence of multiple systems of resistance and multiple copy number of plasmids carrying *mcr-1* gene may have played role in increasing the MIC value of colistin [48]. A multi-country study has reported consistent findings with our study [49]. A previous study from Germany has confirmed a presence of four plasmid carrying *mcr-1* gene within *E. coli* isolates from patients, which indicated the role of *mcr-1* gene for increased MIC of colistin [15].

In this study, the true occurrence of *mcr-1* gene in poultry isolates is 27.6%. Similar result was reported by a study in Iran [50] while a study from Bangladesh reported a higher prevalence (94%) of colistin resistance in ESBLs *E. coli* isolates in poultry [51]. In this study, among 12 colistin resistant isolates, 11 (91.6%) were *mcr-1* positive. The prevalence of *mcr-1* gene is 19.6%. The findings of our study were in line with a study from Italy (8.3% resistance to colistin in hospital surfaces) [52]. The findings of our study, however differed from studies reported from China (low level of colistin resistance) [5], Denmark (higher rate of colistin resistance and presence of 87.5% *mcr-1* gene among colistin resistant *Enterobacteriaceae*) [50], and Korea (14.3% colistin resistance) [9]. Nonetheless, these reports have shown the increasing resistance trend globally.

In this study, 38% and 18% of *mcr-1* positive isolates from poultry and human specimens respectively harbored *OXA-48* genes. This scenario is increasing in Asia and other continent in *E. coli* isolates [53, 54]. Most of the carbapenem resistance reports are concerned about CRE in clinical settings while this study reports CRE among *mcr-1* positive isolates in clinical setting and poultry as well [55]. The presence of both *OXA-48* and *mcr-1* gene within a clinical *E. coli* isolates carried by plasmid is serious threat to public health. This study meanwhile could not predict whether both types were carried by the same plasmid.

### Strengths and limitations

This is the first study from Nepal that investigated the co-existence of *mcr-1* and *OXA-48*. Since poultry remains one of the major sources of food in Nepal, use of antibiotics and its concurrent contribution in development of Antimicrobial Resistance (AMR) warrants an urgent attention to embrace 'one health approach' in Nepal. The findings of this study will be a fundamental reference for policy makers and clinicians to be informed about the characteristics and prevalence of colistin resistance which can subsequently guide the optimal treatment, use of antibiotics and infection control.

While our data clearly showed the presence of plasmid mediated *mcr-1* and *OXA-48* in both settings: poultry

and humans, the findings could have been strengthened by conducting surveillance targeted at regional and national level for a whole picture for Nepal. Lack of whole genome sequencing in this study could not confirm the origin and transferability of the genes from animals to humans or vice-versa. Further studies using multi-locus sequence typing could be useful for epidemiological investigations.

## Conclusion

One fourth and one fifth of the plasmid mediated colistin resistance genes in *E. coli* from poultry specimens and clinical specimens indicate high burden of colistin resistance in Nepal. Furthermore, co-existence of colistin and carbapenem resistant genes; and their co-existence in plasmid DNA of *E. coli* isolates in this study suggests the possible spread to other animal, human and environmental pathogens. Molecular methods can aid in early diagnosis, effective management and potential control of transmission. One health approach is critical to fight against MDR that may have been cross-contaminated from environment, animal food and human beings.

## Abbreviations

AST: Antimicrobial susceptibility test; CAMPS: Cationic antimicrobial cyclic polypeptide; CPE: Cytopathic effect; CRE: Carbapenem resistant *E. coli*; CLSI: Clinical laboratory standard institute; ESBL: Extended spectrum  $\beta$ -lactamase; EUCAST: European committee on antimicrobial susceptibility testing; GNB: Gram negative bacteria; ICU: Intensive care unit; kDa: Kilo-Dalton; LPS: Lipopolysaccharide; MCR: Mediated colistin resistance; MDR: Multi-drug resistance; MIC: Minimum inhibitory concentration; ORF: Open reading frame; PCR: Polymerase chain reaction; UTI: Urinary tract infection; WHO: World health organization; XDR: Extensive/xeno-drug resistance.

## Acknowledgements

We would also like to express our sincere gratitude to all the farmers of poultry farms for providing study samples; all laboratory staff at Kantipur Hospital; Central Department of Microbiology, TU for their technical support and NHRC and UGC for financial support of this work. Above all, we are grateful to the patients for their involvement in this study.

## Authors' contributions

BM and UTS performed sampling and laboratory experiment; NS, BCM, UTS, NA and PG contributed in the supervision of the experiment; UTS, KRR and MRB were involved in data analysis. UTS, NA, KRR and PG contributed to the initial study concept, design, development and funding acquisition; BM, UTS and BD contributed in initial draft of the manuscript. KRR and BA were involved in amendment and drafting of several versions of the manuscript. All authors read and approved the final manuscript.

## Funding

This research was partially supported by NHRC and partially by University Grants Commission, Nepal (UGC-Nepal), Bhaktapur through Faculty Research Grant. We declare that this research is free from interest of funding providers.

## Ethics approval and consent to participate

This study was approved by Ethical Review Board (ERB) of Nepal Health Research Council (NHRC), Kathmandu, Nepal (Reg. No. 494/2018). Written consent was applicable to literate people while verbal consent was approached for the rest subjects. Parents/Guardians were interviewed in case of children. The research was in compliance with the Helsinki Declaration.

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Author details

<sup>1</sup> Central Department of Microbiology, Tribhuvan University, Kirtipur, Kathmandu, Nepal. <sup>2</sup> Kantipur Hospital Pvt. Ltd., Tinkune, Kathmandu, Nepal. <sup>3</sup> Central Veterinary Laboratory, Ministry of Agriculture, Land Management and Cooperatives, Government of Nepal, Tripureshwar, Kathmandu, Nepal. <sup>4</sup> Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Received: 26 May 2020 Accepted: 8 September 2020

Published online: 17 September 2020

## References

- Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis*. 2016;16(2):161–8.
- Zhang J, Chen L, Wang J, Butaye P, Huang K, Qiu H, Zhang X, Gong W, Wang C. Molecular detection of colistin resistance genes (*mcr-1* to *mcr-5*) in human vaginal swabs. *BMC Res Notes*. 2018;11(1):143.
- Mello MMVJ, Simoes FV, Freire SV, Moraes R, Santos RP. Microbial resistance to colistin in consequence of mutations in the *mcr-1* gene of *Escherichia coli*. *MOJ Public Health*. 2018;7(2):59–63.
- Poirel L, Kieffer N, Liassine N, Thanh D, Nordmann P. Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of *Escherichia coli*. *Lancet Infect Dis*. 2016;16(3):281.
- Hu Y, Liu F, Lin Y, Gao GF, Zhu B. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis*. 2016;16(2):146–7.
- Zurfluh K, Nuesch-Inderbinen M, Klumpp J, Poirel L, Nordmann P, Stephan R. Key features of *mcr-1*-bearing plasmids from *Escherichia coli* isolated from humans and food. *Antimicrob Resist Infect Control*. 2017;6:91.
- Gao R, Hu Y, Li Z, et al. Dissemination and mechanism for the *mcr-1* colistin resistance. *PLoS Pathog*. 2016;12(11):e1005957.
- Wu R, Yi LX, Yu LF, Wang J, Liu Y, Chen X, Lv L, Yang J, Liu JH. Fitness advantage of *mcr-1*-bearing IncI2 and IncX4 plasmids in vitro. *Front Microbiol*. 2018;9:331.
- Yoon EJ, Hong JS, Yang JW, Lee KJ, Lee H, Jeong SH. Detection of *mcr-1* plasmids in enterobacteriaceae isolates from human specimens: comparison with those in *Escherichia coli* isolates from livestock in Korea. *Ann Lab Med*. 2018;38(6):555–62.
- Huang X, Yu L, Chen X, Zhi C, Yao X, Liu Y, Wu S, Guo Z, Yi L, Zeng Z, et al. High prevalence of colistin resistance and *mcr-1* Gene in *Escherichia coli* isolated from food animals in China. *Front Microbiol*. 2017;8:562.
- Al Bayssari C, Olaitan AO, Dabboussi F, Hamze M, Rolain JM. Emergence of OXA-48-producing *Escherichia coli* clone ST38 in fowl. *Antimicrob Agents Chemother*. 2015;59(1):745–6.
- Braun SD, Ahmed MF, El-Adawy H, Hotzel H, Engelmann I, Weiss D, Monecke S, Ehrlich R. Surveillance of extended-spectrum beta-lactamase-producing *Escherichia coli* in dairy cattle farms in the Nile Delta, Egypt. *Front Microbiol*. 2016;7:1020.
- Patel G, Bonomo RA. "Stormy waters ahead": global emergence of carbapenemases. *Front Microbiol*. 2013;4:48.
- Skov RL, Monnet DL. Plasmid-mediated colistin resistance (*mcr-1* gene): three months later, the story unfolds. *Eur Surveill*. 2016;21(9):30155.
- Falgenhauer L, Waezsada SE, Yao Y, Imriziolioglu C, Kasbohrer A, Roesler U, Michael GB, Schwarz S, Werner G, Kreienbrock L, et al. Colistin resistance gene *mcr-1* in extended-spectrum beta-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. *Lancet Infect Dis*. 2016;16(3):282–3.
- Pokharel S, Raut S, Adhikari B. Tackling antimicrobial resistance in low-income and middle-income countries. *BMJ Glob Health*. 2019;4(6):e002104.
- Pokharel S, Adhikari B. Antimicrobial resistance and over the counter use of drugs in Nepal. *J Glob Health*. 2020;10(1):010360.



18. Rhouma M, Beaudry F, Letellier A. Resistance to colistin: what is the fate for this antibiotic in pig production? *Int J Antimicrob Agents*. 2016;48:119–26.
19. Elbediwi M, Li Y, Paudyal N, et al. Global burden of colistin-resistant bacteria: mobilized colistin resistance genes study (1980–2018). *Microorganisms*. 2019;7(10):461.
20. Joshi PR, Thummeepak R, Leungtongkam U, et al. The emergence of colistin-resistant *Escherichia coli* in chicken meats in Nepal. *FEMS Microbiol Lett*. 2019;366(20):fnz237.
21. Gurung S, Kafle S, Dhungel B, et al. Detection of OXA-48 gene in carbapenem-resistant *Escherichia coli* and *Klebsiella pneumoniae* from urine samples. *Infect Drug Resist*. 2020;13:2311–21.
22. Isenberg HD. *Clinical microbiology procedures handbook*. 2nd ed. Washington, DC: ASM Press; 2004.
23. Cheesbrough M. *District laboratory practice in tropical countries*. 2nd ed. Cambridge: Cambridge University Press; 2006.
24. Forbes B, Sahm DF, Weissfelt SA. *Bailey and Scott's diagnostic microbiology*. London: Mosby Publication; 2007.
25. Clinical and Laboratory Standards Institute (2018). *Performance standards for antimicrobial susceptibility testing*. 28th edition Informational supplement M100-S28. Wayne PCalsi.
26. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18(3):268–81.
27. Sambrook J, Russell D. *Molecular cloning: a laboratory manual*. 3rd ed. New York: Cold Spring Harbor Lab Press; 2001.
28. Dallenne C, Da Costa A, Decre D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in *Enterobacteriaceae*. *J Antimicrob Chemother*. 2010;65(3):490–5.
29. Dhariwal AK, Tullu MS. Colistin: re-emergence of the 'forgotten' antimicrobial agent. *J Postgrad Med*. 2013;59(3):208–15.
30. El-Sayed Ahmed MAE, Zhong LL, Shen C, Yang Y, Doi Y, Tian GB. Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019). *Emerg Microbes Infect*. 2020;9(1):868–85.
31. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, Venditti M, Bordini E, Capozzi D, Balice MP, et al. High rate of colistin resistance among patients with carbapenem-resistant *Klebsiella pneumoniae* infection accounts for an excess of mortality. *Clin Microbiol Infect*. 2013;19(1):E23–30.
32. Sonnevend A, Ghazawi A, Alqahtani M, Shibli A, Jamal W, Hashmery R, Pal T. Plasmid-mediated colistin resistance in *Escherichia coli* from the Arabian Peninsula. *Int J Infect Dis*. 2016;50:85–90.
33. Qiu J, Jiang Z, Ju Z, Zhao X, Yang J, Guo H, Sun S. Molecular and phenotypic characteristics of *Escherichia coli* isolates from Farmed Minks in Zhucheng, China. *Biomed Res Int*. 2019;2019:3917841.
34. Nguyen NT, Nguyen HM, Nguyen CV, Nguyen TV, Nguyen MT, Thai HQ, Ho MH, Thwaites G, Ngo HT, Baker S, et al. Use of colistin and other critical antimicrobials on pig and chicken farms in Southern Vietnam and its association with resistance in commensal *Escherichia coli* bacteria. *Appl Environ Microbiol*. 2016;82(13):3727–35.
35. Kayastha K, Dhungel B, Karki S, Adhikari B, Banjara MR, Rijal KR, Ghimire P. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella* species in pediatric patients visiting International Friendship Children's Hospital, Kathmandu, Nepal. *Infect Dis (Auckl)*. 2020;13:1178633720909798.
36. Dhungana K, Awal BK, Dhungel B, Sharma S, Banjara MR, Rijal KR. Detection of *Klebsiella pneumoniae* carbapenemase (KPC) and metallo beta-lactamase (MBL) producing Gram negative bacteria isolated from different clinical samples in a Transplant Center, Kathmandu, Nepal. *ASML*. 2019;2(12):60–9.
37. Guragin N, Pradhan A, Dhungel B, Banjara MR, Rijal KR, Ghimire P. Extended spectrum B-lactamase producing Gram Negative bacterial isolates from urine of patients visiting Everest Hospital, Kathmandu, Nepal. *TUJM*. 2019;6(1):26–31.
38. Raut S, Rijal KR, Khatriwada S, et al. Trend and characteristics of *Acinetobacter baumannii* infections in patients attending Universal College of Medical Sciences, Bhairahawa, Western Nepal: a longitudinal study of 2018. *Infect Drug Resist*. 2020;13:1631–41.
39. Pishnian Z, Haeili M, Feizi A. Prevalence and molecular determinants of colistin resistance among commensal *Enterobacteriaceae* isolated from poultry in northwest of Iran. *Gut Pathog*. 2019;11:2.
40. Jafri SA, Qasim M, Masoud MS, Rahman MU, Izhar M, Kazmi S. Antibiotic resistance of *E. coli* isolates from urine samples of Urinary Tract Infection (UTI) patients in Pakistan. *Bioinformation*. 2014;10(7):419–22.
41. Adhikari RP, Shrestha S, Rai JR, Amatya R. Antimicrobial resistance patterns in clinical isolates of enterobacteriaceae from a tertiary care hospital, Kathmandu, Nepal. *Nepalese Med J*. 2018;1(2):74–8.
42. Shrestha A, Bajracharya AM, Subedi H, Turha RS, Kafle S, Sharma S, Neupane S, Chaudhary DK. Multi-drug resistance and extended spectrum beta lactamase producing Gram negative bacteria from chicken meat in Bharatpur Metropolitan, Nepal. *BMC Res Notes*. 2017;10(1):574.
43. Sarker MS, Mannan MS, Ali MY, Bayzid M, Ahad A, Bupasha ZB. Antibiotic resistance of *Escherichia coli* isolated from broilers sold at live bird markets in Chattogram, Bangladesh. *J Adv Vet Anim Res*. 2019;6(3):272–7.
44. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. *Perspect Med Chem*. 2014;6:25–64.
45. Tada T, Nhung PH, Shimada K, Tsuchiya M, Phuong DM, Anh NQ, Ohmagari N, Kirikae T. Emergence of colistin-resistant *Escherichia coli* clinical isolates harboring mcr-1 in Vietnam. *Int J Infect Dis*. 2017;63:72–3.
46. He QW, Xu XH, Lan FJ, Zhao ZC, Wu ZY, Cao YP, Li B. Molecular characteristic of mcr-1 producing *Escherichia coli* in a Chinese university hospital. *Ann Clin Microbiol Antimicrob*. 2017;16(1):32.
47. Moennighoff C, Thomas N, Nienhaus F, et al. Phenotypic antimicrobial resistance in *Escherichia coli* strains isolated from swine husbandries in North Western Germany—temporal patterns in samples from laboratory practice from 2006 to 2017. *BMC Vet Res*. 2020;16(1):37.
48. Migura-Garcia L, González-López JJ, Martínez-Urtaza J, et al. mcr-colistin resistance genes mobilized by Inc X4, IncHI2, and IncI2 plasmids in *Escherichia coli* of pigs and white stork in Spain. *Front Microbiol*. 2020;10:3072.
49. Hadjadj L, Riziki T, Zhu Y, Li J, Diene SM, Rolain JM. Study of mcr-1 gene-mediated colistin resistance in enterobacteriaceae isolated from humans and animals in different countries. *Genes (Basel)*. 2017;8(12):394.
50. Alba P, Leekitcharoenphon P, Franco A, Feltrin F, Ianzano A, Caprioli A, Stravino F, Hendriksen RS, Bortolaia V, Battisti A. Molecular epidemiology of mcr-encoded colistin resistance in *Enterobacteriaceae* from food-producing animals in Italy revealed through the EU harmonized antimicrobial resistance monitoring. *Front Microbiol*. 2018;9:1217.
51. Amin MB, Sraboni AS, Hossain MI, et al. Occurrence and genetic characteristics of mcr-1-positive colistin-resistant *E. coli* from poultry environments in Bangladesh. *J Glob Antimicrob Resist*. 2020;22:546–52 (published online ahead of print, 2020 Apr 25).
52. Caselli E, D'Accolti M, Soffritti I, Piffanelli M, Mazzacane S. Spread of mcr-1-driven colistin resistance on hospital surfaces. *Italy. Emerg Infect Dis*. 2018;24(9):1752–3.
53. Chen CW, Tang HJ, Chen CC, Lu YC, Chen HJ, Su BA, Weng TC, Chuang YC, Lai CC. The microbiological characteristics of carbapenem-resistant *Enterobacteriaceae* carrying the mcr-1 gene. *J Clin Med*. 2019;8(2):261.
54. Manohar P, Shanthini T, Ayyanar R, Bozdogan B, Wilson A, Tamhankar AJ, Nachimuthu R, Lopes BS. The distribution of carbapenem- and colistin-resistance in Gram-negative bacteria from the Tamil Nadu region in India. *J Med Microbiol*. 2017;66(7):874–83.
55. Huang H, Dong N, Shu L, et al. Colistin-resistance gene mcr in clinical carbapenem-resistant *Enterobacteriaceae* strains in China, 2014–2019. *Emerg Microbes Infect*. 2020;9(1):237–45.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.